Biodesix (BDSX) Receivables - Net (2019 - 2026)

Biodesix has reported Receivables - Net for 8 years, with the latest figure at $9.5 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 24.36% year-over-year to $9.5 million; the trailing twelve-month figure through Mar 2026 stood at $9.5 million (up 24.36% YoY), and the FY2025 full-year result was $9.0 million, up 5.03% from the prior year.
• Receivables - Net for Q1 2026 stood at $9.5 million, up from $9.0 million in the prior quarter.
• The five-year high for Receivables - Net was $12.7 million in Q3 2025, with the low at $3.8 million in Q1 2022.
• Historically, Receivables - Net has averaged $7.3 million across 5 years, with a median of $7.6 million in 2025.
• Annual changes were most pronounced in 2022 — Receivables - Net plunged 79.45% — and 2024, when it surged 145.88%.
• Biodesix's Receivables - Net stood at $5.1 million in 2022, then surged by 51.61% to $7.7 million in 2023, then rose by 12.03% to $8.6 million in 2024, then gained by 5.03% to $9.0 million in 2025, then advanced by 5.14% to $9.5 million in 2026.
• The last three Receivables - Net figures came in at $9.5 million (Q1 2026), $9.0 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.